{
  "id": 13464972,
  "title": "Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?",
  "url": "https://urgent.news/2026/10/10/viking-therapeutics-oral-obesity-drug-advances-to-phase-3-testing-is",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-10T16:15:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/10/viking-therapeutics-oral-obesity-drug-advances-to/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": null,
  "summary": "Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?",
        "url": "https://urgent.news/2026/10/10/viking-therapeutics-oral-obesity-drug-advances-to-phase-3-testing-is-13472746",
        "published": "2026-10-10T16:35:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}